 "Govt caps prices of 36 more drugs")
Government has capped the prices of 36 drugs, including those used to treat infections and diabetes, in its latest move to make essential medicines more affordable, a senior official of the country's drug pricing authority said on Friday.
The medicines join the 348 drugs deemed essential which are also subject to price caps. Drug price control has become a particularly contentious issue in India, where drugmakers say prices are already among the lowest in the world.
Drugmakers, including Cipla Ltd , Ranbaxy Laboratories Ltd , and Cadila Healthcare Ltd are among the companies that will be affected by the latest decision, research firm AIOCD Pharmasofttech AWACS Pvt Ltd said.
An official at the department of pharmaceuticals, which controls the drug pricing authority, confirmed the price cap move, but declined to give details.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app